BPTU NEW
| Price | $32 | $45 | $66 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: BPTU | CAS No.: 870544-59-5 |
| Purity: 99.51% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | BPTU |
| Description | BPTU (BMS-646786) is an allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM). Non-nucleotide ligand. Binds receptor outside of the helical bundle. Blocks inhibition of spontaneous contraction of rat and mouse colon induced by electrical field stimulation, nicotine and P2Y agonists. Antithrombotic; reduces platelet aggregation. |
| In vivo | Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetatea (5 mg intramuscular, q 4 wk) is initiated. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.57 mg/mL (8.01 mM), Suspension. DMSO : 35.71 mg/mL (80.17 mM), Sonication is recommended. 10% DMSO+90% Saline : < 3.57 mg/mL (8.01 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. |
| Keywords | thrombosis | P2YReceptor | P2Y1 | P2Y Receptor | P2Y | Inhibitor | inhibit | BPTU | BMS646786 | BMS 646786 | antithrombotic |
| Inhibitors Related | Prasugrel Hydrochloride | Prasugrel | Sodium metatungstate | Regrelor disodium | (±) Clopidogrel hydrogen sulfate | Uridine-5'-diphosphate disodium salt | Uridine triphosphate trisodium salt | ATPγS tetralithium salt | P2Y1/P2Y12 antagonist-1 | Ticagrelor | Diquafosol tetrasodium | cangrelor tetrasodium |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Anti-Viral Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2019-12-25 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY